THE CORPORATE REPUTATION OF THE PHARMA INDUSTRY IN 2015: THE PERSPECTIVE OF PATIENT GROUPS WITH AN INTEREST IN ...

RARE DISEASES

(2nd edition)

Report published by PatientView, May 2016

 

 
 

If you would like more information, or would like to get hold of this report, please use contact details below
 

  • Contact: Alex Wyke

  • Tel: +44-(0)1547-520-965

  • Email: report@patient-view.com

  • Website: http://www.patient-view.com
  • Publication date:  Tuesday, May 17th, 2016
 

About this report

London, May 17th, 2016. This report is based on the findings of a PatientView November 2015-January 2016 survey exploring the views of 199 patient groups worldwide with an interest in rare diseases. The report provides feedback (from the perspective of  patient groups with an interest in rare diseases) on the corporate reputation of the pharma industry during 2015, as well as on the performance of 28 pharma companies for six key indicators that influence corporate reputation. Results are compared with those of other therapy areas from the 2015 survey.

For the purposes of this report, the phrase ‘corporate reputation’ is defined as the extent to which pharma companies are meeting the expectations of patients and patient groups.

 
 
 
 

The six indicators of corporate reputation:

  1. Patient-centricity.
  2. Patient information.
  3. Patient safety.
  4. Useful products.
  5. Transparency.  And ...
  6. Integrity.

The 28 companies analysed:

AbbVie I Actavis I Allergan I Amgen I AstraZeneca I Baxalta I Bayer I Biogen Idec I Boehringer Ingelheim I Bristol-Myers Squibb I Celgene I Gilead I GSK I Janssen I Lilly I Lundbeck I Merck & Co I Merck KGaA I Novartis I Novo Nordisk I Pfizer I Roche I Sandoz I Sanofi I Shire I Takeda I Teva I UCB
 

“ Dans notre domaine de maladies rares où des efforts ont été faits pour impliquer les patients.”

— National France-based patient group specialising in rare neurological diseases

“We wish that pharma companies were more interested in serving populations who may greatly benefit from drug developments, but who may not have the ‘numbers’ required for profitability. Rare-disease patient groups are often ‘left in the dust’.”

— International Ireland-based patient group specialising in a rare neurological condition
 
 

INDUSTRY-WIDE FINDINGS

40.9% of the 199 patient groups with an interest in rare diseases and respondent to the 2015 ‘Corporate Reputation of Pharma’ survey stated that the pharma industry as a whole had an “Excellent” or “Good” corporate reputation that year. The equivalent figure for patient groups from all therapy areas in 2015 was 37.1%. Rare-disease patient groups responding in 2015 ranked the pharma industry 6th out of 8 healthcare-industry sectors for corporate reputation—ahead of for-profit health insurers, and not-for-profit health insurers. Pharma was ranked 5th in 2015's global therapy-wide results.

In 2015, the pharma industry received positive responses for several of its key activities from the 199 patient groups with an interest in rare diseases, including :

  • As many as 66% of the rare-disease patient groups responding to the 2015 ‘Corporate Reputation of Pharma’ survey described the industry as a whole as “Excellent” or “Good” at providing high-quality products of use to patients. This figure, however, was lower than the equivalent from patient groups across all therapy areas.

The percentage of rare-disease patient groups (compared with patient groups from other therapy areas) stating that pharma in 2015 was “Excellent” or “Good” at providing HIGH-QUALITY PRODUCTS
 

Patient groups with an interest in rare diseases are less positive about pharma's record on PATIENT SAFETY than patient groups from other therapy areas.

55% of rare-disease patient groups responding in 2015 thought pharma “Excellent” or “Good” at ensuring patient safety. The equivalent figure among patient groups from all therapy areas in 2015 was 58%.
 

The percentage of rare-disease patient groups (compared with patient groups from other therapy areas) stating that pharma in 2015 was “Excellent” or “Good” at ensuring PATIENT SAFETY
 

HOW COMPANIES PERFORMED FOR CORPORATE REPUTATION IN 2015: RARE DISEASES
     

    · The table on the right shows the ten companies with the best corporate reputation, as measured by rare-disease patient groups in 2015 (and in 2014).

    · Baxalta’s number-one position overall for corporate reputation in 2015—and its big, ten-place, leap up the ranks from 2014—may, in part, be due to the separation of the original Baxter into biopharmaceutical and medical-device entities, providing patient groups with a clearer picture of the activities of the new Baxalta. The company (in its former manifestation as Baxter International) has been working with the haemophilia community for over 60 years, and its focus on the needs of this specific body of patients are obviously appreciated by them.
     
     
     

    END OF STATEMENT

    PatientView is a UK-based research organisation that consults closely with patient groups, and publicises the work of the patient-advocacy movement.
     
    www.patient-view.com